Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients. Moderna’s vaccine, based on its messenger RNA technology, is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer*, in a phase 2 trial. The companies expect to report data in the fourth quarter of this year.
This post is for Market Movers Digest members only.
Subscribe below to get access to this post.